532983 Stock Overview
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
RPG Life Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹494.60|
|52 Week High||₹751.80|
|52 Week Low||₹425.00|
|1 Month Change||-14.83%|
|3 Month Change||-0.76%|
|1 Year Change||10.08%|
|3 Year Change||93.81%|
|5 Year Change||32.32%|
|Change since IPO||1,027.94%|
Recent News & Updates
|532983||IN Pharmaceuticals||IN Market|
Return vs Industry: 532983 exceeded the Indian Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: 532983 exceeded the Indian Market which returned 8.6% over the past year.
|532983 Average Weekly Movement||7.9%|
|Pharmaceuticals Industry Average Movement||6.6%|
|Market Average Movement||7.0%|
|10% most volatile stocks in IN Market||9.7%|
|10% least volatile stocks in IN Market||4.6%|
Stable Share Price: 532983 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 532983's weekly volatility (8%) has been stable over the past year.
About the Company
|1968||1,107||Yugal Kishor Sikri||https://www.rpglifesciences.com|
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, oncology, urology, respiratory, vitamins and minerals, gastro intestinal, pain management, cardio-vascular, etc. primarily under the Lomotil, Lomofen+, Naprosyn, Azoran, Aldactone, and Serenace brand names. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008.
RPG Life Sciences Fundamentals Summary
|532983 fundamental statistics|
Is 532983 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|532983 income statement (TTM)|
|Cost of Revenue||₹1.42b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||31.13|
|Net Profit Margin||11.70%|
How did 532983 perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Is RPG Life Sciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 532983 (₹494.6) is trading below our estimate of fair value (₹645.1)
Significantly Below Fair Value: 532983 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 532983 is good value based on its Price-To-Earnings Ratio (15.9x) compared to the Indian Pharmaceuticals industry average (20.7x).
PE vs Market: 532983 is good value based on its Price-To-Earnings Ratio (15.9x) compared to the Indian market (20.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 532983's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 532983 is overvalued based on its Price-To-Book Ratio (3.2x) compared to the IN Pharmaceuticals industry average (2.7x).
How is RPG Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has RPG Life Sciences performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 532983 has high quality earnings.
Growing Profit Margin: 532983's current net profit margins (11.7%) are higher than last year (10.3%).
Past Earnings Growth Analysis
Earnings Trend: 532983's earnings have grown significantly by 36.3% per year over the past 5 years.
Accelerating Growth: 532983's earnings growth over the past year (28.7%) is below its 5-year average (36.3% per year).
Earnings vs Industry: 532983 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry 12.5%.
Return on Equity
High ROE: 532983's Return on Equity (20.1%) is considered high.
How is RPG Life Sciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 532983's short term assets (₹2.1B) exceed its short term liabilities (₹801.1M).
Long Term Liabilities: 532983's short term assets (₹2.1B) exceed its long term liabilities (₹87.3M).
Debt to Equity History and Analysis
Debt Level: 532983 has more cash than its total debt.
Reducing Debt: 532983's debt to equity ratio has reduced from 30.2% to 0.1% over the past 5 years.
Debt Coverage: 532983's debt is well covered by operating cash flow (22327.6%).
Interest Coverage: 532983's interest payments on its debt are well covered by EBIT (136x coverage).
What is RPG Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 532983's dividend (1.94%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: 532983's dividend (1.94%) is in the top 25% of dividend payers in the Indian market (1.62%)
Stability and Growth of Payments
Stable Dividend: 532983's dividend payments have been volatile in the past 10 years.
Growing Dividend: 532983's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (30.8%), 532983's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (38.9%), 532983's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yugal Kishor Sikri (64 yo)
Mr. Yugal Kishor Choturam Sikri has been Managing Director and Director at RPG Life Sciences Limited since October 1, 2018 He served as an Independent & Non-Executive Director at RPG Life Sciences Limited...
CEO Compensation Analysis
Compensation vs Market: Yugal Kishor's total compensation ($USD505.14K) is above average for companies of similar size in the Indian market ($USD38.56K).
Compensation vs Earnings: Yugal Kishor's compensation has increased by more than 20% in the past year.
Experienced Management: 532983's management team is considered experienced (4.3 years average tenure).
Experienced Board: 532983's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
RPG Life Sciences Limited's employee growth, exchange listings and data sources
- Name: RPG Life Sciences Limited
- Ticker: 532983
- Exchange: BSE
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹8.180b
- Shares outstanding: 16.54m
- Website: https://www.rpglifesciences.com
Number of Employees
- RPG Life Sciences Limited
- RPG HOUSE
- 463, Dr. Annie Besant Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.